Sensyne to market AI tools in the U.S. through Cognizant and Agorai

doctor in hospital hallway using smartphone
Commercial returns will be shared with the NHS, where the products were first developed, following U.S. regulatory approvals and marketing. (vectorfusionart/Shutterstock)

Oxford, U.K.-based Sensyne Health plans to bring its artificial intelligence tools to America, and it’s enlisting IT services giant Cognizant and data infrastructure specialist Agorai to help do it.

The digital health products making the jump will include GDm-Health, therapeutic software prescribed to help manage gestational diabetes; EDGE, a program for monitoring chronic obstructive pulmonary disorder at home; and Support-HF, to track daily vital signs at home following heart failure.

In the U.K., Sensyne also maintains the air pollution monitoring program CleanSpace, and SEND, an early warning system and vital-sign recording platform designed for hospitals.


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

GDm-Health, currently used in 15 National Health System (NHS) trusts and by about 6,100 patients, will be the first of the group to make its U.S. debut. No U.K. patient data will be shared through the agreements, the company said. The products were first developed within the NHS, in collaboration with the University of Oxford before being licensed to Sensyne. 

RELATED: Bayer teams up with AI firm Sensyne Health to mine NHS data for its heart disease pipeline

“Cognizant and Agorai are excellent partners that will enable us to ensure that the full potential of these innovative products, first invented in the U.K.’s NHS, is realised in the U.S. market,” said Lord Paul Drayson, CEO of Sensyne. 

“Following the appropriate regulatory approvals, Cognizant will provide these digital health applications to U.S. health care providers and the commercial return made by Sensyne will be shared with the NHS.”

RELATED: AI data miner Sensyne Health looks to go public with $77M listing

This year, Sensyne partnered up with Bayer to mine anonymized patient data from the NHS to help design trials and develop treatments for cardiovascular disease. This includes genomic sequencing data and real-world evidence.

In the deal, Sensyne describes itself as a “docking station” that oversees the flow of data and insights between the NHS and commercial interests, keeping protected patient information from being sold or transferred to a third party.

A few months later, Bayer spun its AI collaboration with Sensyne into a full-fledged project among its international LifeHubs, which includes innovation centers in France, Germany, the U.S., Singapore and Japan.

Suggested Articles

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

AstraZeneca is linking up with DeepMatter, a big data firm focused on achieving reproducibility in chemistry, to help improve its compound synthesis.